Alignment Healthcare sues CMS over its 2027 Medicare Advantage star ratings
Alignment Healthcare sued CMS over its 2027 Medicare Advantage star ratings, alleging violations of the Administrative Procedure Act. The company claims the ratings were determined improperly, leading to financial and reputational damage. CMS recalculated scores after a similar lawsuit by Clover Health. Alignment seeks a court decision by May 2027.
How this was made
The 30-second read
Why it matters
The lawsuit alleges CMS used technical notes instead of notice-and-comment rulemaking and argues CMS improperly retained methodology elements after Clover, potentially affecting 2027 ratings and the insurer’s bonus economics.
Market read
Investors in MA insurers may reassess litigation-driven uncertainty around 2027 star ratings and quality bonus payments, especially after the cited member mix deterioration.
What to watch
Star ratings are driven by multiple measures and recalculation mechanics; the market may focus on whether the specific metrics at issue for 2027 are likely to be overturned, not just the existence of the lawsuit.
Background
Medicare Advantage star ratings determine quality bonus payments and influence plan selection by enrollees and brokers; courts previously set aside parts of CMS’ methodology in a Clover Health-related ruling.
Ticker impact
Alignment Healthcare sued CMS over its 2027 Medicare Advantage star ratings methodology, alleging CMS violated the Administrative Procedure Act and kept an approach after Clover.
Likely downside pressure or heightened volatility as investors price litigation risk to future star ratings and quality bonus payments.
The article ties the lawsuit to a specific ratings methodology for 2027 and cites a prior-year ratings drop and member mix deterioration, implying material financial and reputational exposure if the methodology is upheld.
Market effects
Highlights regulatory and litigation risk around Medicare Advantage star ratings methodology, which can affect quality bonus expectations across MA insurers.
Primarily US healthcare policy and MA insurer sentiment; limited direct regional spillover beyond US-listed peers.
Low global relevance, but it can influence US healthcare managed-care risk premia for investors with cross-border exposure.
Counterpoint
Even if CMS methodology is challenged, CMS recalculated after Clover and only set aside metrics courts deemed out of bounds, suggesting the 2027 approach may still survive partial legal scrutiny.
Key entities
- companyAlignment Healthcare
Medicare Advantage insurer suing CMS over the 2027 star ratings methodology and claiming reputational and financial harm from a ratings decline.
- regulatorCenters for Medicare & Medicaid Services (CMS)
Federal agency setting the star ratings methodology that Alignment challenges in court.
- companyClover Health
Named in the article as the beneficiary of a prior court ruling that set aside 20 metrics used in 2026 calculations.
